Hoshino Kouki, Harimoto Norifumi, Muranushi Ryo, Araki Kenichiro, Yamanaka Takahiro, Hagiwara Kei, Ishii Norihiro, Tsukagoshi Mariko, Igarashi Takamichi, Tanaka Hiroshi, Watanabe Akira, Kubo Norio, Yokobori Takehiko, Shirabe Ken
Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Surg Case Rep. 2019 Apr 10;5(1):56. doi: 10.1186/s40792-019-0619-4.
Patients with idiopathic thrombocytopenic purpura (ITP) have low platelet counts and an increased risk of complications. Therefore, these patients generally require high-dose immunoglobulin therapy and platelet transfusion. However, thrombopoietin receptor agonists (TPO-RAs) have recently become available for use in the preoperative treatment strategy for intractable ITP. Recent studies have also reported radiofrequency ablation (RFA) or tissue biopsy as perioperative management for thrombocytopenia using TPO-RA. However, no report has described the use of TPO-RA in a case of hepatectomy.
A 76-year-old man presented with intrahepatic cholangiocarcinoma (IHCC) complicated with ITP. His platelet count was 3.5 × 10/μL. To increase platelet levels prior to surgery, romiplostim was administered subcutaneously (70 μg per week for 3 weeks) and eltrombopag was administered orally (25 mg per day for 23 days), as TPO-RA. His platelet count increased to 14.1 × 10/μL. The patient was successfully and safely treated with left hemi-hepatectomy and TPO-RA as preoperative platelet management.
This case suggests that TPO-RA can be effective, and could serve as a new treatment option in the preoperative management of ITP.
特发性血小板减少性紫癜(ITP)患者血小板计数低且并发症风险增加。因此,这些患者通常需要高剂量免疫球蛋白治疗和血小板输注。然而,血小板生成素受体激动剂(TPO-RAs)最近已可用于难治性ITP的术前治疗策略。最近的研究还报告了使用TPO-RA进行射频消融(RFA)或组织活检作为血小板减少症的围手术期管理。然而,尚无报告描述TPO-RA在肝切除术中的应用。
一名76岁男性患有肝内胆管癌(IHCC)并伴有ITP。他的血小板计数为3.5×10/μL。为了在手术前提高血小板水平,皮下注射了罗米司亭(每周70μg,共3周),并口服了艾曲泊帕(每天25mg,共23天),作为TPO-RA。他的血小板计数增加到14.1×10/μL。该患者通过左半肝切除术成功且安全地接受了治疗,并将TPO-RA作为术前血小板管理措施。
该病例表明,TPO-RA可能有效,并可作为ITP术前管理的一种新的治疗选择。